\documentclass{beamer}

\usepackage{amsmath}
\usepackage{filecontents}
\usepackage{biblatex}
\usepackage[utf8]{inputenc}
\bibliography{references}

\newcommand{\titleText}{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry and some Results}

\beamertemplatenavigationsymbolsempty

\begin{document}
\title{\titleText}   
\author{Johan Blakkisrud} 

\institute{Department of Diagnostic Physics, KRN, OUS}

%\logo{
%    \includegraphics[width = 4cm, height = 4cm, keepaspectratio]{figs/OUS.png}
%}
\date{\today} 

%\newcommand{\nologo}{\setbeamertemplate{logo}{}}
%%\newcommand{\tripellogo}{\setbeamertemplate{logo}{
%%
%%	\includegraphics[width = 3.5cm, height = 3.5cm, keepaspectratio]{figs/OUS.png}
%%	\includegraphics[width = 2.5cm, height = 2.5cm, keepaspectratio]{figs/UIO.png}
%%	\includegraphics[width = 2cm, height = 2cm, keepaspectratio]{figs/NORDIC.jpg}
%%
%%}}
%
%\newcommand{\tripellogo}{\setbeamertemplate{logo}{
%
%	\includegraphics[width = 3.5cm, height = 3.5cm, keepaspectratio]{figs/logo_mashup.png}
%
%}}

\frame{\titlepage} 


\frame{\frametitle{Outline}\tableofcontents} 

\frame{\frametitle{Dummy title}

    \centering
    \includegraphics<1>[width = 1.0\linewidth]{slides/tac_show/slide_0.png}
    \includegraphics<2>[width = 1.0\linewidth]{slides/tac_show/slide_1.png}
    \includegraphics<3>[width = 1.0\linewidth]{slides/tac_show/slide_3.png}
    \includegraphics<4>[width = 1.0\linewidth]{slides/tac_show/slide_4.png}
    \includegraphics<5>[width = 1.0\linewidth]{slides/tac_show/slide_5.png}
    \includegraphics<6>[width = 1.0\linewidth]{slides/tac_show/slide_6.png}
    \includegraphics<7>[width = 1.0\linewidth]{slides/tac_show/slide_7.png}

}

\frame{\frametitle{Dummy title}

    \centering
    \includegraphics<1>[width = 1.0\linewidth]{slides/organ_show/slide_organs_0.png}
    \includegraphics<2>[width = 1.0\linewidth]{slides/organ_show/slide_organs_1.png}
    \includegraphics<3>[width = 1.0\linewidth]{slides/organ_show/slide_organs_3.png}
    \includegraphics<4>[width = 1.0\linewidth]{slides/organ_show/slide_organs_4.png}
    \includegraphics<5>[width = 1.0\linewidth]{slides/organ_show/slide_organs_5.png}
    \includegraphics<6>[width = 1.0\linewidth]{slides/organ_show/slide_organs_6.png}

}

\end{document}

%\section{Antibody}
%
%
%{ % Begin no logo
%    \nologo
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \begin{columns}[T]
%	\column{.45\linewidth}
%    
%\begin{itemize}
%	\item
%	    Combine and we get $^{177}$Lu-lilotomab satetraxetan (Betalutin$\textregistered$)
%	\item
%	    Developed by Nordic Nanovector ASA
%	\item
%	    Currently in the multi center phase 1/2 LYMRIT trial for B-cell non-Hodgkin Lymphoma (PI A. Kolstad)
%	    
%    \end{itemize}
%
%    \column{.45\linewidth}
%
%    \vspace{1.5cm}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/betalutin_fig.png}
%
%\end{columns}
%    
%\footnotetext[1]{\tiny{Dahle, Repetto-Llamazares, Mollatt, Melhus, Bruland, Kolstad, Larsen:Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma:Anticancer Research:33:1:85-95:2013}}
%
%}
%
%}
%
%\section{Therapy with 177-Lu-lilotomab satetraxetan}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_full.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_pet.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_ritux.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_lilotomab.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_betalutin.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_planar_spect.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_planar_pet_follow_up.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_blood.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/therapy_time_line/step_full.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/arm1_and_2/plain.png}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate \textbf{therapy with 177-Lu-lilotomab satetraxetan:} Dosimetry and Some results}
%
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/arm1_and_2/diff.png}
%
%}
%
%
%    { % Begin no logo structure here
%	\nologo
%
%    
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_six.png}
%
%
%    }
%    
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_five.png}
%
%
%    }
%    
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_four.png}
%
%
%    }
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_three.png}
%
%
%    }
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_two.png}
%    \footnotetext[1]{\tiny{https://www.healthcare.siemens.co.uk/molecular-imaging/spect-and-spect-ct/symbia-t}}
%
%
%    }
%    
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_one_tum.png}
%    %\includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_minus_one.png}
%
%
%    }
%
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last_tum.png}
%    %\includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/step_last.png}
%
%
%    }
%
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: \textbf{Dosimetry} and Some results}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/full_tum.png}
%    %\includegraphics[width = 0.7\linewidth]{figs/radiation_dosimetry/full.png}
%
%
%    }
%
%}
%
%    \section{and Some results}
%
%    { % Begin part with no logo
%	\nologo
%
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry \textbf{and Some results}}
%
%    }
%    
%    \frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry \textbf{and Some results}}
%    
%    \centering
%    \includegraphics[width = 0.7\linewidth]{figs/tumorA.png}
%    
%    \footnotetext[1]{\tiny{Blakkisrud, Løndalen, Martinsen, Dahle, Holtedahl, Bach-Gansmo, Kolstad, \& Stokke, Tumor absorbed dose for non-Hodgkin's lymphoma patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med, 4/8/2016}}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry \textbf{and Some results}}
%    
%    \centering
%    \includegraphics[width = 1.1\linewidth]{figs/Fig_AB.png}
%
%    %\footnotetext[1]{\tiny{Blakkisrud, Løndalen, Martinsen, Dahle, Holtedahl, Bach-Gansmo, Kolstad, \& Stokke, Tumor absorbed dose for non-Hodgkin's lymphoma patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med, 4/8/2016}}
%    \footnotetext[1]{\tiny{Blakkisrud, Løndalen, Dahle, Turner, Holte, Kolstad \& Stokke. Red Marrow Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med, 1/9/2016}}
%
%}
%
%\frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry \textbf{and Some results}}
%
%%	\begin{columns}[T]
%%
%%	    \column{.45\linewidth}
%%	    
%%	    \centering
%%
%%	    \begin{figure}
%%	    \caption{Red marrow absorbed doses}	    
%%	    \includegraphics[width = 1.2\linewidth]{figs/Fig2.png}
%%	    
%%	    \end{figure}
%%
%%	    \column{.45\linewidth}
%%
%%	    \centering
%%
%%	    \begin{figure}
%%
%%	    \caption{Tumor absorbed doses}	    
%%	    \includegraphics[width = 1.2\linewidth]{figs/tumor_boxplot.png}
%%	    \end{figure}
%%
%%	\end{columns}
%    \centering
%    \includegraphics[width = 1.0\linewidth]{figs/boxplot_cheat.png}
%    \footnotetext[1]{\tiny{Blakkisrud, Løndalen, Martinsen, Dahle, Holtedahl, Bach-Gansmo, Kolstad, \& Stokke, Tumor absorbed dose for non-Hodgkin's lymphoma patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med, 4/8/2016}}
%    \footnotetext[2]{\tiny{Blakkisrud, Løndalen, Dahle, Turner, Holte, Kolstad \& Stokke. Red Marrow Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med, 1/9/2016}}
%
%
%}
%
%} % End no logo
%
%{ % Begin no logo slide
%
%    \tripellogo
%
%\frame{\frametitle{Antibody-radionuclide conjugate therapy with 177-Lu-lilotomab satetraxetan: Dosimetry and Some results}
%
%    \begin{itemize}
%
%	\item
%	    Caroline Stokke, Ph.D (Main supervisor)
%	\item
%	    Ayca Løndalen, MD
%	\item
%	    Tore Bach-Gansmo MD, Ph.D
%	\item
%	    Mona-Elisabeth Revheim, MD Ph.D
%	\item
%	    Jon Erik Holtedahl, MSc
%	\item
%	    Anne Catrine Martinsen, Ph.D
%	\item
%	    Technical personel at Nuclear Medicine, OUS
%	    \vspace{0.1cm}
%	\item
%	    Arne Kolstad, MD, Ph.D (PI LYMRIT trial)
%	\item
%	    Harald Holte, MD, Ph.D
%	\item
%	    Stine Nygaard
%	    \vspace{0.1cm}
%
%	\item
%	    Jostein Dahle, Ph.D
%	\item
%	    Simon Turner, Ph.D
%
%    \end{itemize}
%	
%} % End no logo slides
%
%}
%    
%\end{document}

%\footnotetext[1]{\tiny{Blakkisrud, Løndalen, Martinsen, Dahle, Holtedahl, Bach-Gansmo, Holte, Harald, Kolstad, \& Stokke, Tumor absorbed dose for non-Hodgkinâs lymphoma patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med}}
%\footnotetext[2]{\tiny{Blakkisrud, Løndalen, Dahle, Turner, Holte, Kolstad \& Stokke. Red Marrow Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan, J Nucl Med Date}}
%\footnotetext[1]\tiny{Coffey, Diez-Ferrer, Serrate, David Ciria, Fuente, Arnaudas, Jose Ignacio: Antiferromagnetic Spin Coupling between Rare Earth Adatoms and Iron Islands Probed by Spin-Polarized Tunneling:Scientific Reports:5:13709}
%\footnotetext[1]\tiny{Dahle, Repetto-Llamazares, Mollatt, Melhus, Bruland, Kolstad, Larsen:Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma:Anticancer Research:33:1:85-95:2013}
%\footnotetext[1]\tiny{https://www.healthcare.siemens.co.uk/molecular-imaging/spect-and-spect-ct/symbia-t}
%\footnotetext[1]{\tiny{177Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL) Phase 1/2 Safety and Efficacy Data From Four Different Pre-dosing Regimens}}
